Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?
Reust
C E
CE
University of Missouri-Columbia, USA. reustc@health.missouri.edu
D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D015994:Incidence; D008403:Mass Screening / Q000191:economics* / Q000592:standards*; D065006:Papanicolaou Test; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D014626:Vaginal Smears / Q000191:economics* / Q000592:standards*